Drugs / hVEGF26-104
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02237638 | Apr 2014 → Jan 2020 | metastatic malignant neoplasm | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hVEGF26-104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02237638 ↗ |
| Action | Inhibit | “After binding of the antibodies to endogenous VEGF this hormone will no longer be able to bind to its receptors (VEGFR1 and VEGFR2) and consequently will no longer exert its...” NCT02237638 ↗ |
| Modality | Vaccine | “therapeutic cancer vaccine targeting VEGF” NCT02237638 ↗ |
| Route | Intramuscular | “Eligible subjects will receive three IM injections with hVEGF26-104/RFASE on days 0 (primer), 14 and 28 (boosters).” NCT02237638 ↗ |